View More Recent Stories

Jun 23, 2020 07:00PM Acerus Announces Voting Results for the 2020 Annual Meeting
Jun 3, 2020 07:00AM Acerus Announces Significant Improvement in NATESTO® Insurance Coverage in the United States
May 12, 2020 07:30AM Acerus Reports First Quarter 2020 Financial Results
May 6, 2020 07:30AM Acerus Announces Resignation of Norma Beauchamp As Director
May 5, 2020 07:30AM Acerus to Report First Quarter 2020 Financial Results and Host Investor Call
May 4, 2020 07:30AM Acerus Appoints Dr. Geoff Cotton to Its Board of Directors
Apr 21, 2020 07:30AM Acerus Announces Publication of Results for NATESTO® Spermatogenesis Study in Journal of Urology
Apr 20, 2020 07:30AM Acerus Receives Notice of Deficiency From Health Canada Regarding Avanafil
Apr 2, 2020 07:30AM Acerus Provides Business Update Related to the Impact of COVID-19
Mar 4, 2020 07:00AM Acerus Reports Fourth Quarter and Full Year 2019 Financial Results
Feb 26, 2020 05:00PM Acerus to Report 2019 Financial Results
Feb 21, 2020 09:55AM Acerus Completes Refinancing Transactions Including US$18,000,000 in Gross Proceeds From New Equity Financing
Feb 12, 2020 07:30PM Acerus Announces Private Placement and Refinancing Transactions
Feb 5, 2020 08:30AM Acerus Announces Acceptance of Two NATESTO® Clinical Studies for Presentation at the American Urological Association Annual Scientific Program
Jan 28, 2020 08:30AM Acerus Announces Acceptance of NATESTO® Spermatogenesis Study Results for Presentation at ENDO 2020
Jan 10, 2020 07:00AM Acerus Provides Update on NATESTO® Approval Process in Europe
Dec 18, 2019 07:00AM Acerus Announces Closing of Additional US$6.5 Million Financing From First Generation Capital
Dec 16, 2019 08:30AM Acerus Announces Amendment to Credit Agreement, Waiver of Certain Q4 Financial Covenants and Upcoming Additional Financing From First Generation Capital
Dec 3, 2019 07:00AM Acerus to Present at the 12th Annual LD Micro Main Event Investor Conference on December 10, 2019
Dec 2, 2019 08:05AM Expanded U.S. NATETSO® Partnership Between Acerus Pharmaceuticals and Aytu BioScience Is Now Fully Operational
Nov 14, 2019 07:00AM Acerus Reports Third Quarter and Year-to-Date Fiscal 2019 Financial Results
Nov 6, 2019 07:30AM Acerus to Report Third Quarter 2019 Financial Results and Host Investor Call
Nov 1, 2019 08:30AM Acerus Provides Update on Temporary Unavailability of NATESTO® in Canada and South Korea
Oct 23, 2019 07:00AM Acerus Pharma Hosting Key Opinion Leader Meeting on Unique Clinical Evidence of NATESTO® for Treatment of Hypogonadism
Oct 17, 2019 08:30AM New Data Demonstrates That NATESTO® Increases Serum Testosterone and Improves Symptoms While Maintaining Normal Semen Parameters in Men With Low Testosterone Through Six Months
Oct 17, 2019 08:30AM New Data Demonstrates That NATESTO® Increases Serum Testosterone And Improves Symptoms While Maintaining Normal Semen Parameters In Men With Low Testosterone Through Six Months
Sep 30, 2019 05:00PM Acerus Announces Amendment to Credit Agreement and Waiver of Certain Q3 Financial Covenants
Aug 7, 2019 07:00AM Acerus Reports Second Quarter and Year to Date Fiscal 2019 Financial Results
Aug 2, 2019 05:00PM Acerus Announces Temporary Unavailability of NATESTO® in Canada and South Korea
Aug 1, 2019 08:05AM NATESTO® Spermatogenesis Study Final Results Accepted for Presentation at the American Society for Reproductive Medicine 75th Annual Scientific Conference
Jul 30, 2019 07:00AM Acerus and Aytu Bioscience to Co-promote Natesto® in the United States
Jul 30, 2019 07:00AM Acerus And Aytu Bioscience To Co-Promote NATESTO® In The United States
Jul 29, 2019 07:00AM Acerus to Report Second Quarter 2019 Financial Results and Host Investor Call
Jul 24, 2019 05:00PM Acerus Congratulates US Partner Aytu Bioscience on Listing of NATESTO® on National Pharmacy Benefit Manager’s Formulary
Jul 19, 2019 07:00AM Acerus Announces Closing of US$5 Million Secured Term Loan
Jul 10, 2019 07:00AM Acerus Provides Business Update on NATESTO®
Jul 8, 2019 07:00AM Acerus Announces Publication of Study Results Demonstrating Effectiveness of NATESTO® Regardless of Baseline Symptom Severity
Jun 28, 2019 05:00PM Acerus Announces Amendment to Term Loan Credit Facility
Jun 27, 2019 07:00AM Acerus Provides Update On Avanafil Health Canada Submission
Jun 6, 2019 07:00AM Acerus Reaches Mutual Agreement with Innovus Pharma to Terminate Distribution and License Agreement for UriVarx® in Canada
May 30, 2019 07:00AM Acerus Signs License Agreement to Nasal Technology with University of Texas at Austin
May 13, 2019 07:00AM Acerus Reports First Quarter 2019 Financial Results
May 8, 2019 07:00AM Acerus Approved to Trade on the OTCQB Venture Market under the Symbol ASPCF
View More Recent Stories